Search for a trial

Clinical validation of a dried blood spot (DBS) method for the analysis of immunosuppressive and antifungal drugs in pediatric patients (part of the PROTECT study).

PrimairyTo clinically validate a finger prick DBS method compared to conventional venous sampling for the analysis of 5 immunosuppressive and 4 azole antifungal drugs in the pediatric population. Secondairy• Feasibility of the novel finger prick DBS…

Pharmacologic optimization of voriconazole; a prospective cluster randomized controlled trial of therapeutic drug monitoring

The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more cost-effective compared to…

Bioavailability of voriconazole in critically ill patients

The objective of this study is to obtain the absolute bioavailability of voriconazole in critically ill ICU patients.

T-cell mediated immunity against Aspergillus fumigatus

To study the mechanisms by which T-cells can contribute to the defense against Aspergillus fumigatus.To study the role of the immune system and the role of Aspergillus antigens in the switch from a Th1 to a Th2 profile in patients with ABPA.

the Application of an Electronic Nose in the Early detection of Aspergillosis II

1. To establish whether serial exhaled breath analysis using eNose can detect invasive pulmonary aspergillosis in patients with prolonged chemotherapy induced neutropenia (neutrophil counts <0.5 x 10^9 for more than 7 days).2. To establish…

the Application of an Electronic Nose in the Early detection of ASpergillosis

to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls

Pharmacokinetic Evaluation of POSaconazole boosted Fosamprenavir (EPOS)

Primary: To determine the influence of posaconazole on unboosted fosamprenavir pharmacokinetics, and vice versa, in healthy volunteersSecondary: To determine the safety of combined use of fosamprenavir with posaconazole in healthy vol-unteers

Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease

• To determine the pharmacokinetics of posaconazole (new solid oral and IV) given as prophylaxis to patients who are at risk for developing fungal infections after receiving conditioning therapy (except strictly non myeloablative (NMA)) for…

Fungal infections as complication of monoclonal antibody therapy directed against IL-17 mediated inflammation: estimating incidence and severity and identifying influence of immunogenetics to establish a guideline for screening, prevention and treatment.

1. To estimate the incidence and severity of fungal infections during anti-Th17 mAb therapy2. To characterize the determinants (clinical, immunological, mycobiome/microbiomeand genetical) for developing fungal infections during anti-Th17mAb therapy…

A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001

The study will be performed in 3 parts, Parts 1, 2 and 3. In all parts, the purpose is to investigate to what extent APX001 is tolerated. In addition, it will be investigated how quickly and to what extent APX001 is absorbed and eliminated from the…

Immunological Defects in Chronic Pulmonary Aspergillosis

In this study, we aim to characterize the immunological defect in patients with CPA as compared to patients with chronic obstructive pulmonary disease (COPD) without CPA on a functional, genetic, transcriptional and metabolic level.

Influenza-associated pulmonary aspergillosis (IAPA) in ICU patients with severe influenza: incidence and host- and pathogen related risk factors

A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe…